Lack of modifying effects of 4-ter t-octylphenol and benzyl butyl phthalate on 3,2-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in rats.
The modifying effects of dietary feeding of two estrogenic compounds, 4-tert-octylphenol (tOP) and benzyl butyl phthalate (BBP), on 3,2-dimethyl-4-aminobiphenol (DMAB)-induced prostatic carcinogenesis were investigated in male F344 rats. We also assessed the effects of the test compounds on the proliferating cell nuclear antigen (PCNA) index in induced neoplasms, prostatic intra-epithelial neoplasm (PIN), and non-lesional glands in the prostate. To induce prostatic neoplasms, rats were given subcutaneous injections of DMAB (25 mg/kg body weight) every other week, 10 times in total. They also received the experimental diet containing 10 or 100 ppm tOP and BBP for 40 weeks, starting 1 week after the last dosing of DMAB. DMAB exposure produced prostatic adenocarcinoma with an incidence of 41.2% at the end of the study (week 60). Dietary administration of tOP and BBP did not affect the incidence of prostatic adenocarcinoma: 43.8% in the DMAB --> 10 ppm tOP group; 25.0% in the DMAB --> 100 ppm tOP group; 43.8% in the DMAB --> 10 ppm BBP group; and 43.8% in the DMAB --> 100 ppm BBP group. The PCNA indices in adenocarcinomas, PIN, and non-lesional glands in rats treated with DMAB and tOP or BBP were slightly lower than that of the DMAB alone group, but the differences were not statistically significant. These results might suggest that dietary feeding of the estrogenic compounds tOP and BBP did not modulate DMAB-induced prostatic carcinogenesis in rats.
Kohno
Hiroyuki
H
Department of Pathology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan. h-kohno@kanazawa-med.ac.jp
Suzuki
Rikako
R
Sugie
Shigeyuki
S
Tsuda
Hiroyuki
H
Tanaka
Takuji
T
D000230:Adenocarcinoma / Q000139:chemically induced* / Q000517:prevention & control; D000284:Administration, Oral; D000611:Aminobiphenyl Compounds / Q000633:toxicity*; D000821:Animal Feed; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000633:toxicity*; D004967:Estrogens / Q000819:agonists*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010795:Phthalic Acids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000139:chemically induced / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000517:prevention & control; D051381:Rats; D011916:Rats, Inbred F344
D000611:Aminobiphenyl Compounds; D002273:Carcinogens; D004967:Estrogens; D010636:Phenols; D010795:Phthalic Acids; C001042:2',3-dimethyl-4-aminobiphenyl; C105260:4-tert-octylphenol; C027561:butylbenzyl phthalate